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Abstract
Aim—Assess the burden of congenital and perinatal cytomegalovirus (CMV) disease among 
infants hospitalized in neonatal intensive care units (NICUs).
Methods—CMV infection was defined as a report of positive CMV viral culture or PCR at any 
time since birth in an infant hospitalized in a NICU reporting to California Perinatal Quality Care 
Collaborative during 2005–2010.
Results—156 (1.7 per 1000) infants were reported with CMV infection, representing an 
estimated 5% of the expected number of live births with symptomatic CMV disease. Prevalence 
was higher among infants with younger gestational ages and lower birth weights. Infants with 
CMV infection had significantly longer hospital stays; 14 (9%) died.
Conclusions—Reported prevalence of CMV infection in NICUs represents a fraction of total 
expected disease burden from CMV in the newborn period, likely resulting from underdiagnosis 
and milder symptomatic cases that do not require NICU care. More complete ascertainment of 
infants with congenital CMV infection that would benefit from antiviral treatment may reduce the 
burden of CMV disease in this population.
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In the United States, an estimated 28,000 (0.7%) infants are born with congenital 
cytomegalovirus (CMV) infection annually, 3,600 (12.7%) of whom are estimated to be 
symptomatic at birth [6]. Symptomatic congenital CMV disease is characterized by 
petechiae, purpura, thrombocytopenia, hepatosplenomegaly, direct hyperbilirubinemia, 
microcephaly, intracranial calcifications, chorioretinitis, and hearing impairment [4, 10]. To 
confirm a diagnosis of congenital CMV infection, CMV must be detected in urine, saliva or 
blood within 2–3 weeks of birth [19, 27]. In a study of dried blood samples collected for 
newborn screening, the prevalence of congenital CMV infection was significantly higher 
among preterm and low birth weight infants [13]. As such, the prevalence of congenital 
CMV infection among infants admitted to neonatal intensive care units (NICUs) is likely 
higher than that of the overall population [22, 26, 28].
A subset of the NICU population, infants born <32 weeks gestational age or with a birth 
weight <1500g, is at risk for symptomatic CMV disease [7] from infection acquired peri- or 
postnatally through exposure to infected maternal genital secretions, breast milk, or blood 
transfusion [32]. The risk of CMV transmission by blood transfusion can be reduced by the 
use of CMV-seronegative or leukocyte-reduced blood components [1, 18, 35], which have 
become the standard of care for premature infants in the United States [1, 11, 31]; most 
CMV infections in neonates are likely transmitted by breast milk [7, 17, 34]. The clinical 
characteristics associated with postnatally-acquired CMV infection include hepatopathy, 
thrombocytopenia, neutropenia, petechiae, respiratory distress syndrome, and sepsis-like 
syndrome [7, 34].
Limited data are available on the burden of CMV disease in infancy and the extent to which 
it is severe enough to require hospitalization in NICUs. This study describes demographic 
and clinical characteristics of infants with reported CMV infection in California NICUs 
during 2005–2010 and estimate the proportion of expected live births with symptomatic 
congenital or acquired CMV disease identified in California NICUs during the study period.
METHODS
Study population
The California Perinatal Quality Care Collaborative (CPQCC) collects data for over 90% of 
infants cared for in California NICUs [8, 20]. Eligibility criteria include admission to a 
NICU at birth or within 28 days of life and one of the following: a) birth weight between 
401g–1,500g, b) gestational age between 22 weeks and 29 weeks 6 days, or c) for infants 
with birth weight >1500g, either death, surgery, intubation for >4 hours, positive pressure 
support for >4 hours, hyperbilirubinemia, early bacterial sepsis or acute transfer.
A comprehensive questionnaire including demographics, maternal and delivery history, post-
delivery diagnoses and interventions is used to collect data for each eligible infant. Data are 
abstracted by NICU personnel (i.e. physicians, nurses and other trained abstractors) and 
submitted electronically or on-line. Because the current definition of congenital CMV 
infection used by CPQCC is based on documentation of a positive viral culture or PCR for 
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CMV at any time since birth, it is possible that infants with hospitalizations lasting beyond 
the first 3 weeks after birth had peri- or postanatally acquired CMV infection; 136 (87%) 
infants reported with CMV infection were discharged or died after 3 weeks of life. Specimen 
type and date of collection are not recorded, precluding our ability to verify the diagnosis 
and categorize infants as having congenital or acquired CMV infection.
Data analysis
This study utilized data from 2005–2010 to assess the prevalence of CMV infection per 
1000 live births, using as a denominator the number of live births reported to the CPQCC. 
The following clinical characteristics were available for analysis: antenatal conditions (fetal 
distress, intrauterine growth retardation [IUGR], any anomaly diagnosed prior to birth); 
Apgar at 1st minute, respiratory distress syndrome, neurologic abnormalities (microcephaly, 
seizure, cystic periventricular leukomalacia, and periventricular-intraventricular hemorrhage 
[PIH]); death; and length of hospital stay.
Microcephaly was defined as reported head circumference measured on the day of birth or 
the following day ≤10th percentile according to U.S. growth charts of preterm infants [25]. 
Cystic periventricular leukomalacia and PIH were identified by cranial ultrasound, 
computerized tomographic scan or magnetic resonance imaging performed on or before 28 
days of life. PIH was graded as follows: 0 for no subependymal or intraventricular 
hemorrhage; 1 for subependymal germinal matrix hemorrhage only; 2 for intraventricular 
blood, without ventricular dilation; 3 for intraventricular blood with ventricular dilation; and 
4 for intraparenchymal hemorrhage.
In univariate analyses, clinical characteristics of infants with and without reported CMV 
infection were compared. Analyses of clinical characteristics were performed for very low 
birth weight (VLBW) infants (those with birth weight between 401g–1,500g) and infants 
weighing >1500g. Infants with other congenital or perinatal infections, such as herpes 
simplex virus and HIV, were excluded from the analyses. Statistical analyses, performed 
using SAS version 9.3 (SAS, Cary, NC), were based on Chi-square test or exact test for 
comparison of categorical variables, Chi-square for linear trend, and the Wilcoxon test for 
continuous variables. Statistical analyses were
The proportion of the expected number of live births with symptomatic CMV disease in 
California that was identified in California NICUs was estimated assuming all infants 
reported with CMV infection would have symptomatic disease, given that CMV-specific 
testing among infants in the United States appears to be conducted primarily for diagnostic 
purposes [21]. CPQCC average coverage of California NICUs of 87% (85% during 2005–
2008 and 90% during 2009–2010) was used to extrapolate the number of live births reported 
with CMV infection in CPQCC-member hospitals to the entire state of California. The 
expected number of live births with symptomatic congenital CMV disease was derived 
assuming an annual birth prevalence of congenital CMV infection of 0.7%, with 12.7% of 
infected live births presenting symptomatic congenital CMV disease [6]. The expected 
number of live births with symptomatic acquired CMV disease was estimated assuming that 
symptomatic disease from peri- or postnatally acquired infection was limited to live births 
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<32 weeks gestational age or with a birth weight <1500g, with an incidence rate of 2.4% 
[17].
The study protocol was submitted to the Institutional Review Boards at the Centers for 
Disease Control and Prevention and Stanford University and deemed exempt from further 
review because all data were de-identified.
RESULTS
During 2005–2010, 156 of 91,435 infants in CPQCC-member hospital NICUs were reported 
as having CMV infection; 87 of 33,588 VLBW infants and 69 of 57,847 infants >1500g. 
This corresponds to an overall prevalence of 1.7 infants reported with CMV infection per 
1000 live births requiring NICU care; 2.6 per 1000 among VLBW infants and 1.2 per 1000 
among infants >1500g. The prevalence of CMV infection increased from 1.1 to 2.5 per 1000 
live births during 2005–2010 with marked increases among VLBW infants (1.5 to 4.6 per 
1000 live births) (Figure 1). The prevalence of CMV infection was higher among infants 
with younger gestational age (<32 weeks: 2.4 per 1000, 32–36 weeks: 1.4 per 1000, and ≥37 
weeks: 1.2 per 1000), and among infants with lower birth weight (<1500g: 2.6 per 1000, 
1501g–2500g: 1.8 per 1000, and >2500g: 0.8 per 1000) (P<0.01).
The majority of infants reported with CMV infection were born to mothers 20–29 years of 
age (44%) (Table 1). The prevalence of CMV infection was highest among infants born to 
mothers <20 years of age, 1.8-fold that of infants born to mothers 30–39 years of age. The 
highest prevalence of CMV infection was observed among infants born to Asian/Pacific 
Islander mothers (3.4 per 1000 live births), followed by those born to Hispanics (1.8 per 
1000 live births) and non-Hispanic blacks (1.7 per 1000 live births). Among VLBW infants, 
the prevalence of CMV infection among infants born to Asian/Pacific Islander mothers was 
nearly three-fold that of infants born to non-Hispanic white mothers (PR=2.9; 95%CI-1.5–
5.5). Among infants >1500g, the prevalence of CMV infection among infants born to 
Hispanic mothers was nearly two-fold that of infants born to non-Hispanic white mothers 
(PR=1.9; 95%CI=1.1–3.5).
Overall, IUGR was diagnosed in 25 (17%) infants reported with CMV infection (Table 2), 
and was more common than in infants without CMV infection (Table 2). Among infants 
>1500g, 15 (23%) with CMV infection had anomalies detected prior to birth (brain 
anomalies, cardiac defects, or gastrointestinal malformations) two times as many as those 
without CMV infection (P<0.05). The proportion of infants with Apgar scores ≤3 did not 
differ by CMV status, even after stratification by birth weight. VLBW infants with CMV 
infection were more likely than those without CMV infection to have respiratory distress 
syndrome (OR=2.5; 95%CI=1.3–4.7) (P<0.01). Although only two infants reported with 
CMV infection had microcephaly listed as a congenital anomaly, 19 (14%) infants with 
CMV infection were determined to have head circumference ≤3rd percentile, and 42 (31%) 
had microcephaly (head circumference ≤ 10th percentile). Microcephaly was more common 
among infants with CMV infection (P<0.05).
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Among infants reported with CMV infection, 99% of VLBW infants and 81% of infants 
>1500g were hospitalized in a NICU beginning on in the 1st day of life. Fourteen (9%) 
infants reported with CMV infection died, including 8 (9%) of the VLBW infants and 6 
(9%) of the infants >1500g (Table 2), at a median of 38 (range: 3–99) and 9 (range: 3–107) 
days of life, respectively. Among infants >1500g, the frequency of death was significantly 
higher among those with CMV infection. Among surviving infants with CMV infection, the 
median length of hospital stay was 99 (interquartile range: 72–125) days for VLBW infants 
and 48 (18–76) days for infants >1500g, which was significantly longer than for those 
without CMV infection, 60 (42–86) days for VLBW infants and 14 (8–27) days for infants 
>1500g (P<0.01).
Of a total of 3 272 565 live births in California during 2005–2010, an estimated 3834 would 
have symptomatic CMV disease - 2909 live births with symptomatic congenital CMV 
disease, and 925 VLBW live births with symptomatic acquired CMV disease (Table 3). The 
total number of live births with symptomatic CMV disease identified in California NICUs 
extrapolated from CPQCC data (n=179) represented 5% of the expected number of live 
births with symptomatic CMV disease in the newborn period during 2005–2010; this 
proportion increased from 3% in 2005 to 7% in 2010.
DISCUSSION
Limited data are available on the burden of disease caused by congenital or acquired CMV 
infection among infants in the NICU setting [22, 26, 28]. While congenital CMV infection 
can result in severe disease [4, 10, 15], the proportion of infants with disease severe enough 
to require NICU care is unknown. The overall reported prevalence of CMV infection was 
1.7 per 1000 live births requiring NICU care in California, higher than the estimated 
prevalence of symptomatic congenital CMV disease in the general population (0.9 per 1000 
live births) [6]. However, the proportion of infants identified with CMV infection in NICUs 
represents only a fraction of the total expected burden from symptomatic CMV disease, 
likely resulting from milder symptomatic cases that do not require NICU care. Nonetheless, 
CMV infection was associated with prolonged NICU stays, higher mortality rates, and 
neurological abnormalities.
Data on the prevalence of congenital or acquired CMV infection among NICU infants based 
on screening studies are limited. A study in Canada [33] found a prevalence of congenital 
CMV infection among VLBW infants of 1.5%. Another study in Spain [2] diagnosed 2.3% 
of VLBW infants with congenital CMV infection and 10.2% with peri- or postnatally 
acquired CMV infection. In our study, the true prevalence of CMV disease in NICUs was 
likely underestimated because even clinically apparent CMV infections may not be 
suspected or tested for in a timely manner, laboratory techniques have variable performance 
depending on the specimen type, and not all infections diagnosed may have been reported. 
Typical practice for considering and diagnosing CMV infection among NICU infants is 
currently unknown; the increasing prevalence of CMV infection in recent years of CPQCC 
data could reflect changing practices in CMV testing, diagnosis, and/or reporting, and merits 
further investigation. Some of the infants reported in our study may have had asymptomatic 
CMV infection. Our major limitation was the inability to classify reported infants as having 
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congenital or acquired CMV infection. Because acquired CMV infection might occur in up 
to approximately 10% of VLBW infants [2, 17], screening VLBW infants for CMV 
infection at birth would allow for distinguishing between congenital and acquired CMV 
infection, which have different prognoses for long-term sequelae and might simplify follow-
up of these infants.
In our study, the prevalence of CMV infection increased with younger gestational age and 
lower birth weight. In addition, CMV infection was associated with IUGR both in VLBW 
infants and infants >1500g. The mechanisms by which CMV infection may be associated 
with prematurity and IUGR are not completely understood. Altered placental cytokine 
expression is associated with IUGR, prematurity, and early membrane rupture in uninfected 
pregnancies [3]. Recent studies suggest that CMV infection could result in proinflammatory 
changes with important consequences for placental development and function, virus 
transmission, and fetal viability [9, 30]. Understanding immune mechanisms at the level of 
the placenta associated with CMV transmission is an active area of research with the 
potential to aid the development of vaccines and immunotherapies [29].
Microcephaly is a condition frequently reported among infants with congenital CMV disease 
[4, 10], but it was reported as a congenital anomaly for only 2 infants with CMV infection in 
our study. When the criteria of head circumference ≤10th percentile using appropriate 
population-based growth charts was applied, 31% of infants with CMV infection were 
classified as having microcephaly. Microcephaly was more common among infants with 
reported CMV infection compared to those without CMV infection both among VLBW 
infants and infants >1500g. While nearly all VLBW infants were routinely screened for 
brain abnormalities, among infants >1500g, it was more likely among those reported with 
CMV infection than those without, suggesting that this group more likely has true congenital 
CMV infection for which evaluation for brain abnormalities might be a routine practice. The 
role of neuroimaging is likely to evolve as more experience is gained with use of antiviral 
treatments for infants with congenital CMV-related neurologic abnormalities.
In populations with high maternal CMV seroprevalence, the birth prevalence of congenital 
CMV infection tends to be higher as does the acquisition of CMV through breastfeeding [5, 
12]. A study using dried blood spots from a representative sample of newborns in California 
found the highest maternal IgG CMV seroprevalence in Hispanics (89%), followed by 
Asians (87%), blacks (77%) and whites (57%) [13]. In our study, the prevalence of CMV 
infection was highest among infants born to Asian/Pacific Islander mothers (3.4 per 1000), 
followed by Hispanics (1.8 per 1000), non-Hispanic blacks (1.7 per 1000), and non-Hispanic 
whites (1.2 per 1000). Information on country of origin and other maternal 
sociodemographic variables were not available which could have helped to better understand 
the higher prevalence of CMV infection observed among infants born to Asian/Pacific 
Islander mothers.
Population-based studies are needed to better understand the spectrum of symptomatic 
congenital and acquired CMV disease as well as the sub-groups of infants in whom disease 
is most prevalent. Understanding the proportion of cases of congenital and acquired CMV 
infection that are severe and require NICU care is important for assessing the burden and 
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costs of CMV disease in infancy. In the absence of universal newborn screening most cases 
of congenital CMV infection, both asymptomatic and symptomatic, are likely to be missed. 
Newborn screening for CMV has the potential to identify infants at risk of hearing loss and 
cognitive delays although more data are needed on the interventions these infants would 
need and the benefit that prompt identification through early intervention could provide. 
More complete ascertainment of infants with symptomatic congenital CMV disease may 
facilitate appropriate selection of infants with central nervous system disease who would 
benefit from treatment with antivirals [14, 16, 23, 24]. In addition, data on burden of 
acquired CMV disease in VLBW and premature infants are important for guiding use of 
breast milk in this population [17].
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Table 1










Birth Hospital Level (NICU care level)
Primary 33 (21) 1.2 Reference
Intermediate (II) 10 (6) 1.6 1.4 (0.7–2.8)
Community (IIIA/B) 86 (55) 2.3 2.0 (1.3–2.9)
Regional (IIIC/D) 23 (15) 1.5 1.3 (0.7–2.1)
Non-CCS/Home Birth 4 (3) 0.8 0.7 (0.2–2.0)
Total 156 (100) 1.7
Maternal Age
<20 24 (16) 2.6 1.8 (1.1–3.0)
20–29 69 (44) 1.7 1.2 (0.8–1.7)
30–39 50 (32) 1.4 Reference
40+ 11 (7) 2.2 1.5 (0.8–3.0)
Total 154 (100) 1.7
Maternal Race/Ethnicity
Non-Hispanic White 33 (21) 1.2 Reference
Non-Hispanic Black 14 (9) 1.7 1.5 (0.8–2.8)
Hispanic 78 (50) 1.8 1.6 (1.0–2.3)
Asian/Pacific Islander 27 (17) 3.4 3.0 (1.8–4.9)
Others 3 (2) 1.3 1.1 (0.3–3.5)
Total 155 (100) 1.7
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Table 3
Estimated Proportion of Expected Live Births with Symptomatic Congenital or Acquired CMV Disease 
Identified in California NICUs, 2005–2010
n
Total number of live births in California during 2005–2010 3 272 565
   Number of VLBW live births 38 539
Expected number of live births in California with
   Symptomatic congenital CMV disease (LB*0.7%*12.7%)§ 2909(a)
   Symptomatic acquired CMV disease among VLBW live births (VLBW*2.4%)¥ 925(b)
   Total number of live births with either symptomatic congenital or acquired CMV disease 3834(a+b)
Number of live births reported with CMV infection in CPQCC-member NICUs 156
Number of live births identified with CMV infection in California NICUs extrapolated from CPQCC£ 179(c)




§Estimates of birth prevalence of congenital CMV infection and proportion of symptomatic infants at birth according to a published systematic 
review of the literature [6]
¥Estimates of postnatal CMV disease acquired via consumption of frozen breast milk [17]
£Based on average CPQCC coverage of 87% during 2005–2010
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